Table 3 Clinicopathological characteristics of patients with high risk before and after PSM

Age

64.16 ± 8.17

64.67 ± 9.128

0.659

65.2090 ± 7.83840

64.8358 ± 8.82420

0.796

Gender

< 0.001***

0.287

 Male

83(78.30%)

70(55.56%)

44(65.67%)

38(56.71%)

 Female

23(21.70%)

56(44.44%)

23(34.32%)

29(43.28%)

Histologic type

 Adenocarcinoma

83(78.30%)

100(79.3%)

50(74.62%)

53(79.10%)

  LEP

10(9.43%)

20(15.87%)

7(10.44%)

12(17.91%)

  ACI-PAP

53(50.00%)

45(35.71%)

23(34.32%)

21(29.85%)

  MIP-SOL

20(18.87%)

35(27.78%)

20(29.85%)

20(29.85%)

 Squamous cell carcinoma

19(17.92%)

22(17.46%)

14(20.89%)

12(17.91%)

  Poor differentiated

10(9.43%)

14(11.11%)

10(14.92%)

7(10.44%)

  Moderate/high differentiated

9(8.49%)

8(6.35%)

4(5.97%)

5(7.46%)

 Mixed

4(3.77%)

4(3.17%)

3(4.47%)

2(2.98%)

Number of resected lymph nodes

15.1 ± 5.224

15.59 ± 8.779

0.600

15.5522 ± 7.52226

16.0597 ± 6.91700

0.685

Tumor diameter(mm)

33.44 ± 3.532

33.12 ± 3.969

0.515

33.1642 ± 3.64566

33.5075 ± 3.97101

0.603

Vascular invasion

0.660

0.315

 Yes

3(2.8%)

2(1.5%)

1(1.4%)

0(0%)

 No

103(97.1%)

124(98.4%)

66(98.5%)

67(100%)

Visceral pleural invasion

0.019*

0.723

 Yes

29(27.3%)

54(42.8%)

27(40.2%)

25(37.3%)

 No

77(72.6%)

72(57.1%)

40(59.7%)

42(62.6%)

Recurrence

0.021*

0.042*

 Yes

14(13.2%)

32(25.3%)

9(13.4%)

18(26.8%)

 No

92(86.7%)

94(74.6%)

58(86.5%)

49(71.6%)

Death

0.774

0.628

 Yes

5(4.7%)

7(5.5%)

5(7.4%)

6(8.9%)

 No

101(95.2%)

119(94.4%)

62(92.5%)

61(91.0%)